




European Monitoring Centre
for Drugs and Drug Addiction

Monitoring HCV among PWID in Europe: a set of indicators to serve policy and practice

Isabelle Giraudon
EMCDDA

INHSU 5th International Symposium on Hepatitis Care in Substance users
Oslo 7-9 September 2016



Our aim and objectives

- **Make sure drug users receive treatment**
- Individual benefit, treatment as prevention, equity in access to treatment
- **Work together with the European Member States, ECDC, WHO and other partners, to share, improve and use strategic data and information**
- **In particular monitor HCV epidemiology among PWID and responses in place (backed up by evidence)**
- Integrated indicators - we know what works
- **Support the Member States and monitor the developments of national policies**
- EMCDDA networks: platform to share new initiatives, best practices



EMCDDA – European reference point for drugs

Decentralised EU agency
Formally established in 1993
Based in Lisbon, Portugal

~100 staff
from 16 countries
multidisciplinary team

Network of
30 National Focal points




3

OUR ACTIVITIES

Action on new drugs
Drug-related research
Expert meetings
Hospital emergency data
Key epidemiological indicators
Drug-related deaths and mortality indicator
Drug-related infectious diseases indicator
General population surveys indicator
Treatment demand indicator
High-risk drug use indicator
Markets, crime and supply reduction
Monitoring health and social interventions
Harm reduction interventions
Prevention of drug use
Social reintegration
Drug treatment
Partners
Policy and law
Prison
Scientific award
Wastewater analysis

EMCDDA meeting on the key indicator on Drug-related Infectious Diseases (DRID) 15-16 June 2015 - Lisbon

This year, the DRID key epidemiological indicator meeting focused on the following topics: updating the regional assessment of HIV risk and response; hepatitis C infections and treatment; botulism and other infections; emerging risks related to the injection of stimulants, including new psychoactive substances; and drug-related health issues among prison populations. The meeting kicked off with a summary of the most recent trends and updates by the national experts, based on 2015 'national abstracts' followed by two sets of parallel technical workshops and four 'conference-like' plenaries. Attendance at the expert meeting was restricted to nominated experts from the 28 EU Member States, Norway and Turkey and invited speakers. Our European partners – namely the European Commission and WHO Europe – as well as experts from non-EU countries have contributed to this year's meeting.



Key documents:



- [Meeting Report](#)
- [Final Programme](#)
- [Compilation National Abstracts 2015](#)
- [Participants List](#)

Supporting documents


- [Mission report: HIV and hepatitis B and C in Latvia](#)
- [Wound botulism in people who inject heroin in Norway and the United Kingdom - ECDC/EMCDDA, Lisbon, February 2015](#)
- [Contaminated heroin warning - Wound Botulism - Public Health England](#)



4


HCV antibody prevalence among PWID

HCV antibody prevalence among injecting drug users, 2013/14




| 5

Percentage of high-risk opioid users in agonist maintenance treatment (OST), 2014



| 6

Syringes distributed through specialised programmes per estimated IDU, 2014



| 7

HCV Treatment

- Hepatitis national action plans
- Treatment uptake
- New treatments

FR: Access of all HCV patients to DAAs; use of Fibroscan possible in drug treatment centres/HCV rapid diagnosis tests should be available soon

NL: Dutch Hepatitis Plan/An increasing number of patients treated in outpatient public services for addictive behaviours and dependences are being referred and enrolled in HCV treatment, involving the new oral anti-viral medicaments/For all HCV infected patients (i.e., also for drug users) with a treatment indication, treatment with DAAs is reimbursed

LU: A new national hepatitis action plan, to be launched in the course of 2016, will hopefully allow to increase early diagnosis and improving treatment uptake of PWUD living with hepatitis

UK: Access to the new treatments for HCV is slowly improving, but many HCV infections among PWID remain undiagnosed

DE: INFO study (cohort study to evaluate effectiveness of IFN-free DAAs regimens for the treatment of chronic HCV-infection among OST patients.

DK: Evaluation of action plan for the prevention of hepatitis C

....



| 8

Challenges

In Europe, people who inject drugs (PWID) are likely to be the group most affected by HCV

Significant proportion has not been diagnosed

Lack of access to testing

New risk behaviors, among old and new risk populations, are observed

Stimulant injecting (incl. synthetic cathinones) among MSM and associated with recent outbreaks of HIV in marginalised populations of PWID

New opportunities

DAA's allow successful treatment – if patient diagnosed

Linkage to testing and care a challenge. Exchange of models of good practice is needed.



| 9

The European Drug Report: What is new in the European drug situation?

EUROPEAN DRUG REPORT PACKAGE 2016

A set of interlinked elements allowing full access to the available data and analysis on the drugs problem in Europe

European Drug Report
2016

Trends and Developments
providing a top-level analysis of key developments (print and online)

Statistical Bulletin
containing full data arrays, graphics and methodological information (online)

Perspectives on Drugs
interactive windows on key issues (online)

Country Overviews
national data and analyses at fingertips (online)

Hepatitis C among drug users in Europe
Epidemiology, treatment and prevention

23

www.emcdda.europa.eu



| 10



European Monitoring Centre
for Drugs and Drug Addiction


www.emcdda.europa.eu


Acknowledgements:

To the national focal points and 'Drug-related infectious diseases - DRID' national experts, to the authors of the EMCDDA HCV treatment *Insights* ; Dagmar Hedrich, Eleni Kalamara, Lucas Wiessing, Teodora Groshkova, Roland Simon

Isabelle.Giraudon@emcdda.europa.eu

emcdda.europa.eu

 twitter.com/emcdda

 facebook.com/emcdda

 youtube.com/emcddatube

 flickr.com/photos/emcdda